Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm ZR2 study in relapsed/refractory primary central nervous system lymphoma
ChiCTR2100046986Phase 2Recruiting
- Sponsor
- Affiliated Hospital of Nantong University
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib, rituximab and lenalidomide in primary central nervous system lymphoma (PCNSL), sponsored by Affiliated Hospital of Nantong University. Primary endpoints: Overall response rate, Adverse effects and 2 more. Started Jul 2021; status: recruiting.
02
Drugs
zanubrutinibrituximablenalidomide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on ChiCTR2100046986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046986.